Purinergic receptor antagonists are prodrugs that irreversibly inactivates the target.The later generations improve safety and reduce drug interactions. Warfarin's mechanism of action is related to its structure,special features and safety considerations. Improvements of generations of heparin drugs are based on its binding motif to the target and off-target sites. SAR studies of thiazides. Rational design and the progressive development of ACEIs Selectivity of B-blockers and its relationship to reduced side effects Structures of 1,4-DHP are related to individual drug's specific properties. The steroid nucleus of cardiac glycosides must adopt the U shape Special features of organic nitrates. 4.3.教学内容 4.3.1 Drugs used to treat hyperlipoproteinemics:Statins;Bile acid sequestrants,Fibrates,Others:niacin,ezetimibe,etc. 4.3.2 Drugs used to treat thrombotic conditions Antiplatelets:COX-1 inhibitors;Platelet P2Y purinergic receptor/ADP receptor antagonists;Phosphodiesterase inhibitors, Glycoprotein IIb/IIIa receptor antagonists;Protease-activated receptor-1 (PAR-1)antagonists. Anticoagulants:Oral anticoagulants;Heparin-based anticoagulants;Direct thrombin inhibitors;Direct factor Xa inhibitors; Thrombolytics 4.3.3 Drugs used to treat hypertension Diuretics:Carbonic anhydrase inhibitors;Loop(high-ceiling)diuretics;Thiazides;K+-sparing diuretics Renin-angiotensin pathway blockers:ACE inhibitors;Renin inhibitors;Angiotensin receptor antagonistsPurinergic receptor antagonists are prodrugs that irreversibly inactivates the target. The later generations improve safety and reduce drug interactions. Warfarin's mechanism of action is related to its structure, special features and safety considerations. Improvements of generations of heparin drugs are based on its binding motif to the target and off-target sites. SAR studies of thiazides. Rational design and the progressive development of ACEIs. Selectivity of β- blockers and its relationship to reduced side effects. Structures of 1,4-DHP are related to individual drug's specific properties. The steroid nucleus of cardiac glycosides must adopt the U shape. Special features of organic nitrates. 4.3.教学内容 4.3.1 Drugs used to treat hyperlipoproteinemics: Statins; Bile acid sequestrants; Fibrates; Others: niacin, ezetimibe, etc. 4.3.2 Drugs used to treat thrombotic conditions Antiplatelets: COX-1 inhibitors; Platelet P2Y purinergic receptor / ADP receptor antagonists; Phosphodiesterase inhibitors; Glycoprotein IIb/IIIa receptor antagonists; Protease-activated receptor-1 (PAR-1) antagonists. Anticoagulants: Oral anticoagulants; Heparin-based anticoagulants; Direct thrombin inhibitors; Direct factor Xa inhibitors; Thrombolytics 4.3.3 Drugs used to treat hypertension Diuretics: Carbonic anhydrase inhibitors; Loop (high-ceiling) diuretics; Thiazides; K+-sparing diuretics Renin-angiotensin pathway blockers: ACE inhibitors; Renin inhibitors; Angiotensin receptor antagonists